CompletedPhase 2NCT02366312
A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
Studying Keratocystic odontogenic tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NYU College of Dentistry
- Principal Investigator
- Brian L Schmidt, DDS, MD, PhDNYU College of Dentistry
- Intervention
- vismodegib(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2019
Study locations (1)
- NYU Bluestone Center For Cllinical Research, New York, New York, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02366312 on ClinicalTrials.govOther trials for Keratocystic odontogenic tumor
Additional recruiting or active studies for the same condition.